{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:56:13Z","timestamp":1791618973616,"version":"4.3.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s11523-021-00824-3","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T10:04:25Z","timestamp":1625479465000},"page":"553-568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"16","author":[{"given":"Fausto","family":"Petrelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ghidini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6782-8708","authenticated-orcid":false,"given":"Cinzia","family":"Solinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"824_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21847","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258-66. https:\/\/doi.org\/10.1002\/cncr.21847.","journal-title":"Cancer"},{"key":"824_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1758-y","author":"J Klastersky","year":"2013","unstructured":"Klastersky J, Paesmans M. The multinational association for supportive care in cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer. 2013;21(5):1487-95. https:\/\/doi.org\/10.1007\/s00520-013-1758-y.","journal-title":"Support Care Cancer"},{"key":"824_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat2702","author":"DL Barber","year":"2019","unstructured":"Barber DL, Sakai S, Kudchadkar RR, Fling SP, Day TA, Vergara JA, et al. Tuberculosis following PD-1 blockade for cancer immunotherapy. Sci Transl Med. 2019;11(475):eaat2702. https:\/\/doi.org\/10.1126\/scitranslmed.aat2702.","journal-title":"Sci Transl Med."},{"key":"824_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.12.003","author":"H Picchi","year":"2018","unstructured":"Picchi H, Mateus C, Chouaid C, Besse B, Marabelle A, Michot JM, et al. Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. Clin Microbiol Infect. 2018;24(3):216-8. https:\/\/doi.org\/10.1016\/j.cmi.2017.12.003.","journal-title":"Clin Microbiol Infect"},{"key":"824_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw539","author":"M Del Castillo","year":"2016","unstructured":"Del Castillo M, Romero FA, Arg\u00fcello E, Kyi C, Postow MA, Redelman-Sidi G. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis. 2016;63(11):1490-3. https:\/\/doi.org\/10.1093\/cid\/ciw539.","journal-title":"Clin Infect Dis"},{"key":"824_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.008","author":"DE Magee","year":"2020","unstructured":"Magee DE, Hird AE, Klaassen Z, Sridhar SS, Nam RK, Wallis CDJ, et al. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. Ann Oncol. 2020;31(1):50-60. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.008.","journal-title":"Ann Oncol"},{"key":"824_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","journal-title":"PLoS Med"},{"issue":"23","key":"824_CR8","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/nejmoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207\u201318. https:\/\/doi.org\/10.1056\/nejmoa2017699.","journal-title":"N Engl J Med"},{"key":"824_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919-29. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"N Engl J Med"},{"issue":"11","key":"824_CR10","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/S1470-2045(18)306739","volume":"19","author":"F Barlesi","year":"2018","unstructured":"Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomized, phase 3 study. Lancet Oncol. 2018;19(11):1468\u201379. https:\/\/doi.org\/10.1016\/S1470-2045(18)306739.","journal-title":"Lancet Oncol"},{"issue":"17","key":"824_CR11","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/nejmoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer. N Engl J Med. 2015;373(17):1627\u201339. https:\/\/doi.org\/10.1056\/nejmoa1507643.","journal-title":"N Engl J Med"},{"issue":"10167","key":"824_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomized, open-label, phase 3 study. Lancet. 2019;393(10167):156\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(18)31999-8.","journal-title":"Lancet"},{"issue":"10","key":"824_CR13","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","volume":"21","author":"LA Emens","year":"2020","unstructured":"Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomized, double-blind trial. Lancet Oncol. 2020;21(10):1283\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(20)30465-4.","journal-title":"Lancet Oncol"},{"issue":"6","key":"824_CR14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","volume":"20","author":"C Eng","year":"2019","unstructured":"Eng C, Kim TW, Bendell J, Argil\u00e9s G, Tebbutt NC, Di Bartolomeo M, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomized, controlled trial. Lancet Oncol. 2019;20(6):849\u201361. https:\/\/doi.org\/10.1016\/S1470-2045(19)30027-0.","journal-title":"Lancet Oncol"},{"issue":"10030","key":"824_CR15","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomized controlled trial. Lancet. 2016;387(10030):1837\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(16)00587-0.","journal-title":"Lancet"},{"issue":"19","key":"824_CR16","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/nejmoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856\u201367. https:\/\/doi.org\/10.1056\/nejmoa1602252.","journal-title":"N Engl J Med"},{"issue":"6","key":"824_CR17","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","volume":"30","author":"Y Fradet","year":"2019","unstructured":"Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up. Ann Oncol. 2019;30(6):970\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdz127.","journal-title":"Ann Oncol"},{"issue":"16","key":"824_CR18","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1200\/JCO.19.03091","volume":"38","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, et al. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer. J Clin Oncol. 2020;38(16):1797\u2013806. https:\/\/doi.org\/10.1200\/JCO.19.03091.","journal-title":"J Clin Oncol"},{"issue":"22","key":"824_CR19","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/nejmoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392. https:\/\/doi.org\/10.1056\/nejmoa1801005.","journal-title":"N Engl J Med"},{"issue":"1","key":"824_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","volume":"22","author":"JW Goldman","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide versus platinum\u2013etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomized, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30539-8.","journal-title":"Lancet Oncol"},{"issue":"10027","key":"824_CR21","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet. 2016;387(10027):1540\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7.","journal-title":"Lancet"},{"issue":"14","key":"824_CR22","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/nejmoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328\u201339. https:\/\/doi.org\/10.1056\/nejmoa1917346.","journal-title":"N Engl J Med"},{"key":"824_CR23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0229sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220-9. https:\/\/doi.org\/10.1056\/NEJMoa1809064.","journal-title":"N Engl J Med"},{"key":"824_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.028","author":"R Jotte","year":"2020","unstructured":"Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodr\u00edguez-Abreu D, Hussein M, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous non-small-cell lung cancer (IMpower131): Results from a randomized phase III trial. J Thorac Oncol. 2020;15(8):1351-60. https:\/\/doi.org\/10.1016\/j.jtho.2020.03.028.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"824_CR25","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomized, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(19)30626-6.","journal-title":"Lancet Oncol"},{"issue":"7","key":"824_CR26","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700\u201312. https:\/\/doi.org\/10.1016\/S1470-2045(14)70189-5 (Epub 2014 May 13).","journal-title":"Lancet Oncol"},{"issue":"11","key":"824_CR27","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","volume":"17","author":"CJ Langer","year":"2016","unstructured":"Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomized, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497\u2013508. https:\/\/doi.org\/10.1016\/S1470-2045(16)30498-3.","journal-title":"Lancet Oncol"},{"issue":"8","key":"824_CR28","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer J-U, et al. A randomized phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279\u201388. https:\/\/doi.org\/10.1093\/annonc\/mdz158.","journal-title":"Ann Oncol"},{"issue":"2","key":"824_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1504627 (Epub 2015 May 31).","journal-title":"N Engl J Med"},{"issue":"10257","key":"824_CR30","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): A randomized, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090\u2013100. https:\/\/doi.org\/10.1016\/S0140-6736(20)31953-X.","journal-title":"Lancet"},{"issue":"10183","key":"824_CR31","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomized, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(18)32409-7.","journal-title":"Lancet"},{"issue":"17","key":"824_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"6736","author":"T Powles","year":"2017","unstructured":"Powles T, Dur\u00e1n I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomized controlled trial. Lancet. 2017;6736(17):1\u201311. https:\/\/doi.org\/10.1016\/S0140-6736(17)33297-X.","journal-title":"Lancet"},{"issue":"13","key":"824_CR33","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/nejmoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218\u201330. https:\/\/doi.org\/10.1056\/nejmoa2002788.","journal-title":"N Engl J Med"},{"issue":"12","key":"824_CR34","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomized, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1574\u201388. https:\/\/doi.org\/10.1016\/S1470-2045(20)30541-6.","journal-title":"Lancet Oncol"},{"issue":"31","key":"824_CR35","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","volume":"34","author":"M Reck","year":"2016","unstructured":"Reck M, Luft A, Szczesna A, Havel L, Kim S-W, Akerley W, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740\u20138. https:\/\/doi.org\/10.1200\/JCO.2016.67.6601.","journal-title":"J Clin Oncol"},{"issue":"5","key":"824_CR36","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","volume":"31","author":"A Ribas","year":"2013","unstructured":"Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31(5):616\u201322. https:\/\/doi.org\/10.1200\/JCO.2012.44.6112.","journal-title":"J Clin Oncol"},{"issue":"12","key":"824_CR37","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/nejmoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116\u201327. https:\/\/doi.org\/10.1056\/nejmoa1816714.","journal-title":"N Engl J Med"},{"issue":"5","key":"824_CR38","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","volume":"6","author":"NA Rizvi","year":"2020","unstructured":"Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, et al. Durvalumab with or without tremelimumab vs. standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 2020;6(5):661\u201374. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0237.","journal-title":"JAMA Oncol"},{"issue":"21","key":"824_CR39","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Cs\u0151szi T, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 Study. J Clin Oncol. 2020;38(21):2369\u201379. https:\/\/doi.org\/10.1200\/JCO.20.00793.","journal-title":"J Clin Oncol"},{"issue":"22","key":"824_CR40","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/nejmoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108\u201321. https:\/\/doi.org\/10.1056\/nejmoa1809615.","journal-title":"N Engl J Med"},{"issue":"24","key":"824_CR41","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/nejmoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288\u2013301. https:\/\/doi.org\/10.1056\/nejmoa1716948.","journal-title":"N Engl J Med"},{"issue":"7","key":"824_CR42","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomized, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924\u201337. https:\/\/doi.org\/10.1016\/S1470-2045(19)30167-6.","journal-title":"Lancet Oncol"},{"issue":"10236","key":"824_CR43","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S0140-6736(20)30417-7","volume":"395","author":"L Zimmer","year":"2020","unstructured":"Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;395(10236):1558\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(20)30417-7.","journal-title":"Lancet"},{"key":"824_CR44","doi-asserted-by":"publisher","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. 2019. https:\/\/doi.org\/10.1002\/9781119536604.","DOI":"10.1002\/9781119536604"},{"key":"824_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.06.004","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol. 2011;64(12):1311-6. https:\/\/doi.org\/10.1016\/j.jclinepi.2011.06.004.","journal-title":"J Clin Epidemiol"},{"key":"824_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010042","author":"L Belluomini","year":"2021","unstructured":"Belluomini L, Caldart A, Avancini A, Dodi A, Trestini I, Kadrija D, et al. Infections and immunotherapy in lung cancer: a bad relationship? Int J Mol Sci. 2021;22(1):42. https:\/\/doi.org\/10.3390\/ijms22010042.","journal-title":"Int J Mol Sci"},{"key":"824_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113383","author":"T Gambichler","year":"2020","unstructured":"Gambichler T, Reuther J, Scheel CH, Susok L, Kern P, Becker JC. Cancer and immune checkpoint inhibitor treatment in the era of SARS-CoV-2 infection. Cancers. 2020;12(11):3383. https:\/\/doi.org\/10.3390\/cancers12113383.","journal-title":"Cancers (Basel)."},{"key":"824_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001145","author":"T Gambichler","year":"2020","unstructured":"Gambichler T, Reuther J, Scheel CH, Becker JC. On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19. J Immunother Cancer. 2020;8(2):e001145. https:\/\/doi.org\/10.1136\/jitc-2020-001145.","journal-title":"J Immunother Cancer"},{"key":"824_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.07.129","author":"F Petrelli","year":"2018","unstructured":"Petrelli F, Ardito R, Borgonovo K, Lonati V, Cabiddu M, Ghilardi M, et al. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2018;103:7-16. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.129.","journal-title":"Eur J Cancer"},{"key":"824_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq196","author":"J de Naurois","year":"2010","unstructured":"de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21(Suppl_5):v252-6. https:\/\/doi.org\/10.1093\/annonc\/mdq196.","journal-title":"Ann Oncol"},{"key":"824_CR51","first-page":"255","volume":"17","author":"JA Thompson","year":"2020","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. Management of immunotherapy related toxicities. NCCN Clin Pract Guidel Oncol. 2020;17:255\u201389.","journal-title":"NCCN Clin Pract Guidel Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-021-00824-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-021-00824-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-021-00824-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:08:41Z","timestamp":1744715321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-021-00824-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["824"],"URL":"https:\/\/doi.org\/10.1007\/s11523-021-00824-3","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"11 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Fausto Petrelli, Anna Maria Morelli, Andrea Luciani, Antonio Ghidini, and Cinzia Solinas declare that they have no conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data and material are available on request from the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"FP, AMM, and CS extracted the data; FP performed the statistical analysis; FP, AMM and CS drafted the manuscript; all coauthors participated in writing the final version of the work by providing intellectual input and approving its submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}